Atrial fibrillation: Epidemiologic considerations and rationale for conversion and maintenance of sinus rhythm

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 8, Issue SUPPL. 1, 2003, Pages

  Singh, Bramah N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Antifibrillatory actions; Atrial fibrillation; Atrial selective antiarrhythmic drugs; Epidemiology

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; AZIMILIDE; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; IBUTILIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; RSD 1235; SOTALOL; TEDISAMIL; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; AGING; ANTIARRHYTHMIC ACTIVITY; DRUG CHOICE; DRUG SELECTIVITY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART MUSCLE BLOOD FLOW; HUMAN; MORTALITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION;

EID: 0042315331     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840300800103     Document Type: Review

References (85)

1. Feld GK. Evolution of diagnostic and interventional cardiac electrophysiology: A brief historical review. Am J Cardiol 84:115R-124R, 1999
2. Prystowsky EN, Benson Jr D, Fuster V, et al. Management of patients with atrial fibrillation: A statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology. American Heart Association. Circulation 93(6):1262-1277, 1996
3. Singh BN, Mody FM, Lopez B, Sarma JSM. Antiarrhythmic agents for atrial fibrillation: Focus on prolonging atrial repolarization. Am J Cardiol 84:161R-173R, 1999
4. Hohnloser S. Rhythm or rate control in atrial fibrillation: Insights from the randomized controlled trials. J Cardiovasc Pharmacol Therapeut 8:in press, 2003
5. Nattel S. Atrial electrophysiology and mechanism of atrial fibrillation. J Cardiovasc Pharmacol Therapeut 8:in press, 2003
6. Braunwald E. Shattuck lecture. Cardiovascular medicine at the turn of the turn of millennium: Triumphs, concerns and opportunities. N Engl J Med 337:1360-1369, 1997
7. Scheinman MM. Atrial fibrillation and congestive heart failure: The intersection of two common diseases. Circulation 98:941-942, 1998
8. Alpert JS. Atrial fibrillation: A growth industry in the 21st century. Eur Heart J 21:1207-1208, 2000
9. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, and predisposing conditions for atrial fibrillation: Population-based estimates. Am J Cardiol 82:2N-9N, 1998
10. Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol 84:131R-138R, 1999
11. 2001 Heart and Stroke Statistical Update, Dallas, Texas: American Heart Association, 2000
12. Bureau of the Census Statistic Brief. Sixty-five Plus in the United States. Department of Commerce, Economics, and Statistics Administration. Bureau of the Census, 1995
13. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults. JAMA 285:2370-2375, 2001
14. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort study: The Framingham Heart Study. JAMA 271:840-844, 1994
15. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju RM. Prevalence of atrial fibrillation in elderly subjects: The Cardiovascular Health Study. Am J Cardiol 74:238-241, 1994
16. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 22:983-988, 1991
17. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Arch Intern Med 155:469-473, 1995
18. Philips SJ, Whisnant J, O'Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes in residents of Rochester, Minnesota. Mayo Clin Proc 65:344, 1990
19. Lakatta EG. Cardiovascular aging without clinical diagnosis. Dialog Cardiovasc Med 6:67, 2001
20. Bharati S, Lev M. Histology of the normal and diseased atrium. In: Falk RH, Podrid PJ, eds. Atrial Fibrillation: Mechanisms and Management. New York: Raven Press, 1992
21. Davies MJ, Pomerance A. The pathology of atrial fibrillation in man. Br Heart J 34:520-525, 1972
22. Kopecky SL, Gersh BJ, McGoon, et al. The natural history of atrial fibrillation. A population-based study over three decades. N Engl J Med 317:669-674, 1987
23. Tsang TS, Gersh BJ. Atrial fibrillation: An old disease, a new epidemic. Am J Med 113:432-435, 2002
24. Wolf PA, Benjamin EJ, Belanger AJ, et al. Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am Heart J 131:790-795, 1996
25. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation 98:946-952, 1998
26. Tsang TS, Petty T, O'Fallon W, et al. The changing prevalence of atrial fibrillation in men and women of Rochester, Minnesota: A population based study, 1960-1989, J Am Coll Cardiol 39(Suppl B): 61B, 2002
27. Vidaillet H, Granada JF, Chyou, et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 113:365-370, 2002
28. Stewart S, Hart CL, Hole DJ, McMurray JJV. A population based study of the long-term risks associated with atrial fibrillation: 20 year follow-up of the Renfrew/Paisley Study. Am J Med 113:359-364, 2002
29. Bigger JT. Epidemiological and mechanistic studies of atrial fibrillation on a basis for treatment strategies. Circulation 98:943-945, 1998
30. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-up Study. Am J Med 98:476-484, 1995
31. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 22:983-988, 1991
32. 2001 Heart and Stroke Statistical Update. Texas: American Heart Association, 2000
33. Gajewski J, Singer RB. Mortality in insured population with atrial fibrillation. JAMA 245:1540-1544, 1981
34. Lip G. Does atrial fibrillation confer a hypercoagulable state? Lancet 346:1313-1314, 1995
35. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: The Framingham study. N Engl J Med 285:1441-1446, 1971
36. Deedwania PC, Singh BN, Ellenbogan K, Fisher S, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation 25:2574-2579, 1998
37. Pozolli, Cioffi G, Traversi E, et al. Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: A prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 32:197-204, 1998
38. Redfield M, Kay G, Jenkins L, et al. Tachycardia-related cardiomyopathy: A common cause of ventricular dysfunction in patients with referred for atrioventricular ablation. Mayo Clin Proc 75:790-795, 2000
39. Stevenson WG, Stevenson LW. Atrial fibrillation in heart failure. N Engl J Med 34:910-911, 1999
40. Shinbane J, Wood M, Jensen D, et al. Tachycardia-induced cardiomyopathy: A review of animal models and clinical studies. J Am Coll Cardiol 29:709-715, 1997
41. Tsang TSM, Gersh BJ, Appleton, et al. Left ventricular diastolic dysfunction: An important predictor of first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 40:1636-1644, 2002
42. Kitzman DW. Why is diastolic heart failure in older patients the cardiologist's enigma. Dialog Cardiovasc Med 6:95, 2001
43. Ezekowitz MD, Jalife J. Why is the aging heart prone to atrial fibrillation and what should be done about it? Dialog Cardiovasc Med 6:112, 2001
44. Tsang T, Barnes M, Bailey K, et al. Left atrial volume: Important risk marker of incident atrial fibrillation in 1655 older men and women. May Clin Proc 76:467-475, 2001
45. Singh BN. Antiarrhythmic drugs: A re-orientation in light of recent developments in the control of disorders of rhythm. Am J Cardiol 81(6A):3D-13D, 1998
46. Nattel S, Singh BN. Evolution, mechanisms, and classification of antiarrhythmic drugs: Focus on Class III actions. Am J Cardiol 84(9A): 11-19, 1999
47. Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrpophysiol 10:272-282, 1998
48. Singh BN. Currrent antiarrhythmic drugs: An overview of mechanisms of action and potential clinical utility. J Cardiovasc Electrpophysiol 10:283-301, 1998
49. Singh BN, Wadhani N, Sarma JSM. Rate dependence of antiarrhythmic action. J Cardiovasc Pharmacol Therapeut 7:203-206, 2002
50. Singh BN, Vaughan Williams EM. A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 39:675-687, 1970
51. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new antianginal drug, cardiac muscle. Brit J Pharmacol 39:657-667, 1970
52. Singh BN. Pharmacological actions of certain cardiac drugs and hormones: Focus on antiarrhythmic mechanisms. D. Phil. Thesis, Hertford College & University of Oxford. England. Published also by Futura Publishing Co, Mt Kisco, NY1991 pp 1-98, 1971
53. Vaughan Williams EM. Classification of antiarrhythmic drugs. E. Sandoe, E Flenstedt-Johnson, KH Olesen (Eds): Symposium on Cardiac Arrhythmias. AB Astra, Sodertalje, Sweden. pp 440-469, 1970
54. Singh BN. A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function. Cardiovasc Res 6:109-119, 1972
55. Singh BN, Hauswirth O. Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J 87:367-382, 1974
56. Singh BN, Williams EM. Effect of altering potassium concentration on the action of lidocaine and diphenylhydantoin on rabbit atrial and ventricular muscle. Circ Res 29:286-295, 1971
57. Hauswirth O, Singh BN. Ionic mechanisms in heart muscle in relationship to the genesis and the pharmacological control of cardiac arrhythmias. Pharmacol Rev 30:5-63, 1979
58. Hoffman BF, Bigger JT Jr. Antiarrhythmic drugs. In: DiPalma JR, (ed). Drill's Pharmacology in Medicine, 4th edition. New York: McGraw-Hill Book Co. pp 824-852, 1971
59. Harrison DC. Is there a rational basis for the modified classification of antiarrhythmic drugs? In: Morganroth J, Moore EN (eds). Cardiac Arrhythmias: New Therapeutic Drugs and Devices. Martinus Nijhoff, Boston, 36-48, 1985
60. Hondeghem LM, Snyders DJ. Class III anti-arrhythmic agents have a lot of potential but a long way to go: Reduced effectiveness and dangers of reverse use dependence. Circulation 81:686-692, 1990
61. Dorian P, Newman D. Rate dependence of the effect of antiarrhythmic drugs delaying cardiac repolarization: An overview. Europace 2:277-285, 2000
62. Dorian P, Dunnman P, Elstun L, Newman D. The effect of isoproterenol on the class III action azimilide in humans. J Cardiovasc Pharmacol Therapeut 8, in press, 2003
63. Chen F, Esmalian F, Sun W, Wetzel GT, Sarma JSM, Singh BN, et al. Azimilide inhibits multiple cardiac potassium currents in human atrial myocytes. J Cardiovasc Pharmacol Therapeut 7:255-264, 2002
64. Sun W, Sarma JSM, Singh BN. Electrophysiologic effects of dronedarone (SR33589), a non-diodinate benzfuran derivative, in the rabbit heart. Comparison with amiodarone. Circulation 100:2276-2283, 1999
65. Sager PT, Uppal P, Follmer CT, Antimisiaris M, Pruitt C, Singh BN. The frequency-dependent electrophysiologic effects of amiodarone in humans. Circulation 88:1063-1068, 1993
66. Singh BN, Sarma JSM. Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias. J Cardiovasc Pharmacol Therapeut 1:69-87, 2001
67. Papp J Gy, Nemeth M, Krassoi I, Mester L, Hala O, Varro A. Differential electro-physiologic effects of chronically administered amiodarone on canine Purkinje fibers versus ventricular muscle. J Pharmacol Exp Therapeut 1(4): 187-96, 1996
68. Sicouri S, Moro S, Litovsky S, Elizari M, Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. J Cardiovasc Electrophysiol 8:1269-1276, 1997
69. Cui G, Sen L, Sager PT, Uppal P, Singh BN. Effects of amiodarone, sematilide and sotalol on QT dispersion. Am J Cardiol 75:465-469, 1995
70. Wang Z, Pelletier LC, Talajic M, Nattel S. Effects of flecainide and quinidine on human atrial potentials: Role of rate dependence and comparison with guinea pig, rabbit and dog tissues. Circulation 82:274-283, 1990
71. Fermini B, Jurkiewicz NK, Jow B. Use dependent effect of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization block or delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 26:259-267, 1995
72. Salata JJ, Brooks RR. Pharmacology of azimilide dihydrochloride (NE-10064), a class III antiarrhythmic agent. Cardiovas Drug Rev 15:137-156, 1997
73. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 22:810-818, 1993
74. Restivo M, Hegazy M, El-Hamamy M. Antiarrhythmic efficacy of azimilide hydrochloride on functional circus movement atrial flutter in the canine right atrial enlargement model. PACE 19(4, part ii):664, 1996
75. Corey AE, Al-Khalidi H, Brezovic C, et al. Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing. Clin Pharmacol Ther 61:205-212, 1997
76. Pritchett E, Page, R, Connolly S, Marcello S. Azimilide treatment of atrial fibrillation. Circulation 98:1:633, 1998
77. Camm AJ, Karam R, Pratt CM. The azimilide post-infarct survival evaluation (ALIVE) trial. Am Cardiol 81:35D-39D, 1998
78. Sun W, Sarma JSM, Singh BN. Chronic and acute effects of dronedarone and the action potential of rabbit atrial muscle preparations: Comparison with amiodarone. J Cardiovasc Pharmacol 39:677-684, 2002
79. Ks in guinea pig ventricular myocytes. Fund Clin Pharmacol 13: 389-395, 1999
80. Bargheer K, Bode F, Klein HU, et al. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur Heart J 15:1409-1414, 1994
81. Wallace AA, Stupienski RF, Baskin EP, et al. Cardiac electrophysiologic actions of tedisamil. J Pharmacol Exp Ther 273:168-175, 1995
82. Chi L, Park JL, Fredrichs GS, et al. Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br J Pharmacol 117:1261-1269, 1996
83. Dorian P. Antiarrhythmic drug therapy of atrial fibrillation: Focus on new agents. J Cardiovasc Pharmacol Therapeut 8: in press, 2003
84. Hesketh JC, Fedida D. Draft report of Effects of RSD and RSD1385 upon action potentials recorded from the rabbit atrium and ventricle. Cardiome Pharma Corp, August 1st, 2001 (unpublished)
85. Baskin EP, Lynch JJ Jr. Differential atrial versus ventricular activities of class III potassium channel blockers. J Pharmacolo Exp Ther 285(1):135-142, 1998